Amryt Pharma (Amryt Pharma) Buyback Yield % : 0.00 (As of Jun. 07, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Amryt Pharma's current buyback yield was 0.00%.

Amryt Pharma Buyback Yield % Historical Data

The historical data trend for Amryt Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Buyback Yield % Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Buyback Yield %

Get a 7-Day Free Trial

-25.93

-7.49

-0.68

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amryt Pharma's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Buyback Yield % falls into.

Amryt Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Amryt Pharma's Buyback Yield for the fiscal year that ended in Dec. 2021 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	4.701)	/	690.8004
	=	-0.68%

Amryt Pharma's annualized Buyback Yield for the quarter that ended in Sep. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	442.684164
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2022) data.

Amryt Pharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).